Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology (NYSE: MAIA) has announced a private placement offering of 463,332 shares of common stock at $1.50 per share to accredited investors and a Company director. The offering includes warrants to purchase an equal number of shares at $1.71 per exercise price, exercisable after six months with a five-year term. The private placement is expected to close around May 29, 2025, with anticipated gross proceeds of approximately $695,000.
The company plans to use the proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act.
MAIA Biotechnology (NYSE: MAIA) announced the acceptance of their abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase efficacy data from their Phase 2 THIO-101 clinical trial of ateganosine (THIO), a telomere targeting agent, in combination with cemiplimab for third-line immune checkpoint inhibitor-resistant advanced NSCLC.
The poster, titled "Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC: Evaluation of Overall Survival," will be presented by Dr. Tomasz Jankowski on May 31, 2025, from 1:30 PM to 4:30 PM CDT in the Lung Cancer track. CEO Vlad Vitoc expressed confidence in ateganosine's potential to become a best-in-class anticancer treatment.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. The offering includes warrants to purchase one share of common stock at $2.05 per share, exercisable one year after issuance with a six-year term.
The private placement is expected to close around May 7, 2025. The proceeds will be used to fund the initiation of Part C of the Phase II THIO-101 trial and for working capital. Securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the Company's 2021 Equity Incentive Plan.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.05, exercisable after six months with a five-year term. The placement is expected to close around May 7, 2025.
The company plans to use the proceeds to fund the initiation of Part C of their Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the company's 2021 Equity Incentive Plan.
MAIA Biotechnology (NYSE: MAIA) has outlined key clinical milestones for 2025 in a shareholder letter from CEO Vlad Vitoc. The company's lead compound THIO (ateganosine) is highlighted as the only clinical-stage telomere-targeting anticancer agent in cancer discovery.
Key developments include:
- Phase 2 trial THIO-101 expansion is ongoing with potential FDA filing for accelerated approval in 2026
- Phase 3 THIO-104 trial scheduled to begin mid-2025, with potential filing for early full approval in 2026
- THIO demonstrates exceptional efficacy in advanced non-small cell lung cancer (NSCLC)
- Multiple additional THIO trials planned for various cancer indications
The company is pursuing multiple regulatory pathways for THIO in NSCLC treatment, targeting significant market opportunities in hard-to-treat cancers with unmet medical needs.